Immunotherapy in the adjuvant treatment of patients with malignant melanoma

Abstract

The possibilities of adjuvant treatment of malignant melanoma have expanded and improved in recent years. The original adjuvant treatment with interferon alfa was replaced by modern immunotherapy with checkpoint inhibitors and, in a case of the BRAF mutation, also by targeted therapy.

The following article provides a basic summary of the use of adjuvant immunotherapy in malignant melanoma.

Keywords

• malignant melanoma
• interferon alfa, nivolumab
• pembolizumab
• adjuvant therapy